Array Technologies, Inc. fell 11.4% on Monday, November 9, 2026, on 14,740,600 shares. The headline around the move:
Array Technologies, Inc. (ARRY:NASDAQ) closed at $4.84 on November 13, 2026, up 0.83% on the day. The stock trades 60.4% below its 52-week high of $12.23 and 56.6% above its 52-week low of $3.09. Over the past year, it lost 40.8%. Array Technologies, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ARRY closed higher on 115 days (46%). Its best day was November 3, 2026 (+22.11%) and its worst was February 26, 2026 (-33.82%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 3 times.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company's Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headqu...
Find more stocks like ARRY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.